DNFB activates MAPKs and upregulates CD40 in skin-derived dendritic cells

Area of Science:

• Immunology
• Dermatology
• Cell Biology

Background:

• Intracellular mechanisms of dendritic cell (DC) activation in allergic contact dermatitis (ACD) sensitization remain unclear.
• Understanding DC activation is crucial for developing targeted ACD therapies.

Purpose of the Study:

• Investigate the impact of 2,4-dinitrofluorobenzene (DNFB), a potent sensitizer, on mitogen-activated protein kinase (MAPK) activity in fetal skin-derived dendritic cells (FSDCs).
• Correlate DNFB-induced MAPK activation with the expression of CD40, a key marker of DC maturation.

Main Methods:

• Western blot analysis to quantify phosphorylated ERK1/2 (pERK1/2) and p38 MAPK (pp38 MAPK), and CD40 protein levels.
• Immunocytochemistry to determine the cellular localization of activated MAPKs.
• Utilized specific MAPK inhibitors (SB203580, SB202190, PD 98059, U0126) to assess their role in CD40 upregulation.

Main Results:

• DNFB significantly activated ERK1/2 and p38 MAPK, leading to nuclear translocation of their phosphorylated forms.
• DNFB treatment markedly increased CD40 protein expression in FSDCs.
• An inactive DNFB analogue, 2,4-dichloronitrobenzene (DCNB), did not affect MAPK phosphorylation or CD40 levels.
• Inhibition of p38 MAPK partially reduced DNFB-induced CD40 upregulation, but not significantly.
• MEK inhibitors (PD 98059, U0126) did not impact DNFB-mediated CD40 upregulation.

Conclusions:

• DNFB activates ERK1/2 and p38 MAPK signaling pathways in FSDCs.
• DNFB treatment leads to increased CD40 protein levels, a marker of DC maturation.
• While DNFB activates MAPKs, these pathways do not appear to play a major role in the induction of CD40 during DC maturation in this model.